-

$undefined

N/A

(N/A)

MannKind Corporation NASDAQ:MNKD MannKind Corporation focuses on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, its first FDA-approved product and the only inhaled ultra rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. MannKind is headquartered in Westlake Village, California, and has a state-of-the art manufacturing facility in Danbury, Connecticut.

Location: 30930 Russell Ranch Rd Ste 300, California, 91362-7379, United States | Website: www.mannkindcorp.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing

Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

1.822B

Cash

253.1M

Avg Qtr Burn

N/A

Short % of Float

15.80%

Insider Ownership

1.86%

Institutional Own.

50.89%

Qtr Updated

06/30/24

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Afrezza® (insulin human) Inhalation Powder Details Diabetes, Type 1 diabetes, Type 2 diabetes	Phase 4 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Tyvaso DPI (Treprostinil Technosphere®) (inhaled treprostinil) Details Pulmonary arterial hypertension, Heart disease	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Afrezza® (insulin human) Inhalation Powder Details Type 1 diabetes, Diabetes, Type 2 diabetes Big Mover™ Suspected Mover™ Susp. Mover™	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Clofazimine inhalation suspension (MNKD 101) Details Lung disease, Nontuberculous mycobacterial lung disease	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
MNKD 201 (nintedanib DPI) Details Lung disease, Idiopathic pulmonary fibrosis	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.